May 19, 2020

AFL Legend Jim Stynes dies at age 45

Australia
AFL
Melbourne
Cancer
Bizclik Editor
2 min
AFL Legend Jim Stynes dies at age 45

Melbourne Demons champion Jim Stynes, 45, died after an enduring and inspiring fight with cancer. His wife, Samantha, and children, Matisse and Tiernan, survive him.

This Irish-born gentleman stole the hearts and earned the respect of Footy fans and Australians alike. The end of Jim’s two-year battle with a rare melanoma was "pain-free, dignified and peaceful," Samantha said. She added that Jim’s “lesson was that life was to be challenged and treasured."

A Victorian and Melburnian of the Year, Jim left his mark on the field when he became the first international player to earn the prestigious Brownlow Medal in 1991. He was also an Order of Australia recipient.

Jim’s heart exceeded that of the goal lines. He touched the lives of countless young Australians as the cofounder of Reach. This organization is recognized as making a positive impact for youth across Australia.

"On behalf of everyone at Reach, our deepest sympathies go to Jim’s equally courageous wife Sam, their two young children, Matisse and Tiernan, and the entire Stynes family," said Reach Chairman Don McLardy in a release. "They will all forever be a part of the Reach family."

Since Jim announced his diagnosis in July 2009, it was a highly publicised journey. The choice to publicly fight a battle so many have to endure earned him the respect and favour of those similarly affected. A televised documentary revealed how deeply the cancer changed Jim’s and his family’s lives.

Jim used twitter to stay connected with those through his journey. In his passing, fans, believers, survivors and friends are now sharing their condolences.

The AFL tweeted: The AFL is saddened to learn of the passing of an icon of our game, Jim Stynes. Our thoughts and prayers are with his family.

Jim leaves the message to cherish life and what is truly important:

"I have had an experience that in some ways, I am very blessed," he once said. "I have had an insight that not many people get. When you are faced with that prospect, it does make you sit back, stop and go OK, what is really important now? You realise your family - my kids and my wife Sam - they are everything to me. It's not just enough to say it - you've got to live it."

Read the March issue of Business Review Australia

Share article

Jun 13, 2021

Seo JungJin: Who is EY’s World Entrepreneur of 2021?

EY
entrepreneurs
Leadership
celltrion
Kate Birch
3 min
From just US$45,000 capital in 2003 to a world-leading biopharma giant with revenues of US$1.69bn today, Seo JungJin is crowned EY World Entrepreneur 2021

Seo JungJin, founder of biopharma firm Celltrion, which most recently developed an antibody treatment for COVID-19, has been named the EY World Entrepreneur of the Year 2021, becoming the first South Korean in the award’s 21-year history.

Regarded as one of the world’s most prestigious business awards program for entrepreneurs, the EY Entrepreneur of the Year celebrates visionary and innovative leaders from across 60 countries who are transforming the world and fostering growth.

JungJin, who is now honoroary chairman of Celltrion Group, was up against a worthy cast of entrepreneurial competitors, taking the crown from among 45 award winners across 38 countries and territories.

Speaking during the virtual event, JungJin described his own interpretation of entrepreneurship as something that brings together “a group of people toward a common vision, embracing challenges as opportunities and committing oneself to contribute to the greater good”.

Why was JungJin crowned King Entrepreneur?

A South Korean native and now 63 years of age, JungJin founded biopharmaceutical firm Celltrion in 2003. In the nearly two decades since its founding, Celltrion has lived up to its goal of advancing health and welfare for all by developing ground-breaking drugs to treat autoimmune disease, various forms of cancer and, most recently, COVID-19.

The company, which JungJin started with just US$45,000 and five of his colleagues, has since growth to more than 2,1000 employees with sales permits in more than 90 countries and revenues exceeding US$1.69bn.

According to the panel, JungJin’s story is a shining example of the power of an unstoppable entrepreneur to change the world with the pandel moved by both his incredible story and his purpose-driven leadership, innovative mindset and entrepreneurial spirit.

Described by the chair of the EY judging panel Rosaleen Blair as “representing everything an unstoppable should be” from taking on the world’s biggest health care challenges to consistently creating long-term value for his company, JungJin’s story is one of incredible tenacity and perseverance that the judging panel felt most represented the entrepreneurial spirit.

“He’s taken breathtaking risks, both personal and professional, to found Celltrion and grow it into one of the world’s leading biopharmaceutical companies,” says Stasia Mitchell, EY Global Entrepreneurship Leader. “His passion for creating affordable, life-saving health care and flair for tackling global problems has led to many treatments that have helped millions of people worldwide and was especially evident this past year through the creation of a COVID-19 antibody treatment.”

How did JungJin get there?

JungJin's entrepreneurial journey started at an early age when he worked as a taxi driver to get himself through Konkuk University in Seoul, South Korea. After studying industrial engineering, he rose through the ranks of Daewoo Motor Co. before losing his job amid the carmaker’s financial troubles following the 1997 Asian economic crisis.

Following this, JungJin started collaborating with colleagues to explore business opportunities in different industries, though none delivered lasting success. The turning point came after he attended a talk hosted by renowned scholars, which inspired him to focus on the biopharmaceutical sector.

And so he founded Celltrion with just US$45,000 of his savings. The launch of Remsima, credited with being the world's first antibody biosimilar, quickly moved Celltrion up the ranks of the country's fairly underdeveloped pharmaceutical sector. Celltrion followed this success with the launch of drugs for breast cancer and lymphoma that today are being used worldwide.

With ambitions to be the world’s first in different areas, Celltrion has pioneered numerous uncharted areas to great success over the past two decades, most recently responding to the global pandemic by successfully developing an antibody treatment for COVID-19 and working to ensure a timely supply of the safe and effective treatment.

“When I first started, my vision was to help patients gain access to safe, effective and affordable medicines and thereby enhance the quality of people’s lives,” explains JungJin. “The success of Celltrion has enabled me to expand on this while finding new ways to fuel my entrepreneurial drive.”

 

Share article